|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Alternative polyadenylation (APA) site-switching of 3'UTRs is prevalent in NSCLC, and CSTF2 may serve as an oncogene regulates the 3'UTR length of cancer related genes in NSCLC.
|
31391087 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Alternative polyadenylation (APA) site-switching of 3'UTRs is prevalent in NSCLC, and CSTF2 may serve as an oncogene regulates the 3'UTR length of cancer related genes in NSCLC.
|
31391087 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Alternative polyadenylation (APA) site-switching of 3'UTRs is prevalent in NSCLC, and CSTF2 may serve as an oncogene regulates the 3'UTR length of cancer related genes in NSCLC.
|
31391087 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our findings also suggest a CSTF2-regulated <i>RAC1</i>-3'UTR shortening program as an exploitable therapeutic strategy for patients with UCB.<b>Significance:</b> These findings demonstrate that the short isoform of <i>RAC1</i> is critical in UCB tumorigenesis and may have implications for developing new therapeutic strategies to treat this disease.<i>Cancer Res; 78(20); 5848-62.©2018 AACR</i>.
|
30143523 |
2018 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our findings also suggest a CSTF2-regulated <i>RAC1</i>-3'UTR shortening program as an exploitable therapeutic strategy for patients with UCB.<b>Significance:</b> These findings demonstrate that the short isoform of <i>RAC1</i> is critical in UCB tumorigenesis and may have implications for developing new therapeutic strategies to treat this disease.<i></i>.
|
30143523 |
2018 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
CSTF2 regulated the tumorigenic functions of the shorter <i>RAC1</i> isoform in UCB cells, enhancing cell proliferation, migration, and invasion.
|
30143523 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Our findings also suggest a CSTF2-regulated <i>RAC1</i>-3'UTR shortening program as an exploitable therapeutic strategy for patients with UCB.<b>Significance:</b> These findings demonstrate that the short isoform of <i>RAC1</i> is critical in UCB tumorigenesis and may have implications for developing new therapeutic strategies to treat this disease.<i>Cancer Res; 78(20); 5848-62.©2018 AACR</i>.
|
30143523 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis using tissue microarray showed an association of strong CSTF2 expression with poor prognosis of patients with non-small cell lung cancer (P = 0.0079), and multivariate analysis showed that CSTF2 positivity is an independent prognostic factor.
|
21813631 |
2011 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
CSTF2 is likely to play an important role in lung carcinogenesis and be a prognostic biomarker in the clinic.
|
21813631 |
2011 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, suppression of CSTF2 expression by siRNAs suppressed lung cancer cell growth, whereas exogenous expression of CSTF2 promoted growth and invasion of mammalian cells.
|
21813631 |
2011 |
|
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that AGO2 and CSTF2 can be considered as potential theoretical biomarkers for MS and can be helpful for diagnosis and prognosis of responding patients to interferon.
|
30610590 |
2019 |
|
Carcinoma, Transitional Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
CSTF2-Induced Shortening of the <i>RAC1</i> 3'UTR Promotes the Pathogenesis of Urothelial Carcinoma of the Bladder.
|
30143523 |
2018 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings also suggest a CSTF2-regulated <i>RAC1</i>-3'UTR shortening program as an exploitable therapeutic strategy for patients with UCB.<b>Significance:</b> These findings demonstrate that the short isoform of <i>RAC1</i> is critical in UCB tumorigenesis and may have implications for developing new therapeutic strategies to treat this disease.<i></i>.
|
30143523 |
2018 |
|
Urothelial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CSTF2-Induced Shortening of the <i>RAC1</i> 3'UTR Promotes the Pathogenesis of Urothelial Carcinoma of the Bladder.
|
30143523 |
2018 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, suppression of CSTF2 expression by siRNAs suppressed lung cancer cell growth, whereas exogenous expression of CSTF2 promoted growth and invasion of mammalian cells.
|
21813631 |
2011 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, suppression of CSTF2 expression by siRNAs suppressed lung cancer cell growth, whereas exogenous expression of CSTF2 promoted growth and invasion of mammalian cells.
|
21813631 |
2011 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, suppression of CSTF2 expression by siRNAs suppressed lung cancer cell growth, whereas exogenous expression of CSTF2 promoted growth and invasion of mammalian cells.
|
21813631 |
2011 |
|
Enterovirus Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation.
|
19779565 |
2009 |
|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
A time-course study to monitor the expression levels of CstF-64 in EV71-infected cells also revealed that the reduction of CstF-64 during virus infection was correlated with the production of viral 3C(pro).
|
19779565 |
2009 |